Stock Analysis
Intellia Therapeutics, Inc. (NTLA) Stock Analysis
Intellia Therapeutics, Inc. (NTLA) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Intellia Therapeutics, Inc. (NTLA) currently has an AIQ Score of 41/100, indicating a neutral setup. Momentum is the strongest factor at 64/100. Quality is the weakest current factor at 28/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
NTLA at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $12.47 |
| AIQ Score | 41/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $1.77B |
| P/E Ratio (TTM) | -3.78 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | -$0.80 |
| Revenue (quarter ended 2026-06-30) | $7.66M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.79 |
| Volume | 4.09M |
| 52-week range | $7.95-$18.48 |
| RSI 14 | 51.55 |
| 50-Day SMA | $12.23 |
| 200-Day SMA | $13.08 |
| Analyst Price Target | $20.25 |
| Next Earnings | Nov 5, 2026 |
NTLAIntellia Therapeutics, Inc.
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum64
- Value34
- Quality28
- Risk resilience42
- Sentiment—
NTLA Stock Analysis Summary
Intellia Therapeutics, Inc. (NTLA) currently has an AIQ Score of 41/100, indicating a neutral setup. Momentum is the strongest factor at 64/100. Quality is the weakest current factor at 28/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, NTLA has AIQ Score of 41/100 with Momentum base of 64/100 and fading Quality at 28/100. Wait for component alignment before adding exposure.
Momentum (64/100) leads while Quality (28/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -5.74% stock move · NTLA classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is NTLA Bullish or Bearish Right Now?
NTLA currently has a neutral overall setup. Momentum is the strongest factor at 64/100, while Quality is weakest at 28/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 64/100.
- - Price is +8.16% above its 50-day SMA.
- - Analyst target implies +62.39% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (35 vs 6).
- - Value is the current constraint at 34/100.
- - Risk Resilience is weak at 42/100.
Current Consensus
NTLA's Technical Analysis Consensus is currently Strong Buy, with 35 buy, 4 neutral, and 6 sell votes. NTLA's 14-day RSI is 51.55, which places the stock in a neutral momentum range. NTLA's beta is 1.79, indicating greater market sensitivity than the broad market.
What Changed in NTLA?
The largest recent change in NTLA is Momentum moving up by 31.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the NTLA Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
NTLA Decision Framework
Public evidence layers, setup checks, and risk context for Intellia Therapeutics, Inc..
Intellia Therapeutics, Inc. (NTLA) Stock Analysis
Intellia Therapeutics, Inc. has an AIQ Score of 41/100 in a Neutral regime. Momentum is strongest at 64/100. Beta is 1.8, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | NTLA is in a Neutral AIQ regime with score 41/100. |
| Signal Conflict | The primary conflict is that momentum leads at 64/100 while quality lags at 28/100. |
| Factor Evidence | Momentum 64/100 · Value 34/100 · Quality 28/100 · Risk 42/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 64/100.
Momentum is 64/100 and RSI (14) is 51.6.
NTLA is in a Neutral regime at 41/100.
Risk factor is 42/100 with beta 1.8 and annual volatility 79.7%.
Current conflict: momentum leads at 64/100 while quality lags at 28/100.
NTLA Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
NTLA Fundamentals
NTLA valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
NTLA Technical Analysis
NTLA technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
NTLA Stock Catalysts
Track NTLA earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
NTLA Dividend Analysis
NTLA dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
NTLA Financial Data
NTLA revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
NTLA Risk Analysis
NTLA volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
NTLA Stock News
NTLA stock news, market tone, recent headlines, and catalyst context.
NTLA vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: NTLA · NUVB · PRMB · RARE · RCKT. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| NTLA Current stock | 41/100 | 34/100 | 64/100 | 42/100 | 0.36 | 79.70% | Current |
| NUVB Nuvation Bio | 39/100 | 34/100 | 36/100 | 43/100 | 0.22 | 82.00% | NTLA vs NUVB |
| PRMB Preimmune | 39/100 | 49/100 | 45/100 | 49/100 | -0.03 | 49.34% | NTLA vs PRMB |
| RARE Ultragenyx Pharmaceutical | 51/100 | 50/100 | 53/100 | 22/100 | -0.43 | 81.79% | NTLA vs RARE |
| RCKT Rocket Pharmaceuticals | 37/100 | — | 41/100 | 48/100 | -0.3 | 68.41% | NTLA vs RCKT |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 29, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts4 recent quarterly periods are available for review.
Checked Oct 31, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching NTLA
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for NTLA
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
NTLA Stock FAQ
What is NTLA stock price today?
Intellia Therapeutics, Inc.'s current stock price is $12.47. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is NTLA bullish or bearish right now?
NTLA's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is NTLA's market cap?
NTLA's market cap is $1.77B based on the latest completed market-close snapshot from Oct 30, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is NTLA's current P/E ratio?
NTLA's current P/E ratio is -3.78 based on the latest completed market-close snapshot from Oct 30, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is NTLA's RSI?
NTLA's 14-day RSI is 51.55 based on the latest completed market-close snapshot from Oct 30, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is NTLA above its 50-day and 200-day moving averages?
NTLA is 8.16% from its 50-day SMA and 1.16% from its 200-day SMA based on the latest completed market-close snapshot from Oct 30, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is NTLA's next earnings date?
NTLA's next earnings date is currently listed as Nov 5, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does NTLA pay a dividend?
NTLA's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 30, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.